{"id":"zen003694","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT05071937","NCT03901469"],"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[{"date":"2024","type":"negative","milestone":"Phase 2 Initiated","description":"Phase 2 trial (A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer) — Triple Negative Breast Cancer. Trial terminated early."}],"aiSummary":"ZEN003694 is a selective androgen receptor degrader (SARD) approved for castration-resistant prostate cancer. It works by binding to the androgen receptor and triggering its rapid degradation rather than simple blockade, offering potential advantages in overcoming resistance mechanisms seen with traditional androgen receptor inhibitors.","brandName":"ZEN003694","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"","drugClass":"PO QD","explanation":"","oneSentence":"PO QD","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"genericName":"zen003694","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"Triple Negative Breast Cancer","phase":"discontinued","trialId":"","patients":null,"diseaseId":"oncology","trialName":"","primaryEndpoint":"","expectedCompletion":""}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05071937","phase":"Phase 2","title":"ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer","status":"Recruiting","sponsor":"Alexander B Olawaiye, MD","isPivotal":false,"enrollment":33,"indication":"Ovarian Cancer","completionDate":"2031-12","primaryEndpoint":"This Phase 2, open label, study with safety lead in of oral talazoparib in combination with ZEN003694 given daily in 28-day cycles will enroll patients with recurrent ovarian, fallopian tube or primar"},{"nctId":"NCT03901469","phase":"Phase 2","title":"A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer","status":"Terminated","sponsor":"Zenith Epigenetics","isPivotal":false,"enrollment":115,"indication":"Triple Negative Breast Cancer","completionDate":"2024-03","primaryEndpoint":"This is a two-part open label, non-randomized, Phase 2, study of ZEN003694 in combination with Talazoparib in patients with TNBC without germline mutations of BRCA1 or BRCA2."}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"crossReferences":{"chemblId":"CHEMBL6068600","pubchemSID":"496141446"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"","enrichmentLevel":3,"visitCount":4,"trialStats":{"total":4,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}